The synergy of dual and triple incretin agonists in increasing bodyweight loss through decreased appetite and increased energy expenditure may offer an advanced therapeutic option for patients with obesity, and several novel unimolecular peptides are in clinical development (Table 2). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.